Larazotide

Mechanism of action

Larazotide acetate (AT-1001) is a synthetic octapeptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) originally derived from a structural sequence of the Vibrio cholerae surface protein zonula occludens toxin (Zot). Zot binds to host receptors in the intestinal epithelium, triggering a signalling cascade that results in redistribution of tight-junction proteins — occludin, claudin-1, claudin-3, and zonula occludens-1 (ZO-1) — away from the intercellular junction, thereby increasing paracellular permeability. The endogenous mammalian analogue of this process is mediated by zonulin (pre-haptoglobin-2), a protein secreted by intestinal epithelial cells and hepatocytes in response to gliadin exposure (among other triggers) that opens tight junctions through the same epidermal-growth-factor-receptor (EGFR) and protease-activated-receptor-2 (PAR-2) signalling pathways that Zot exploits. Elevated intestinal zonulin has been reported in coeliac disease, type-1 diabetes, and non-coeliac gluten sensitivity. Larazotide is proposed to act as a competitive antagonist of the receptor site through which Zot and, by extension, zonulin signal. By occupying this receptor, larazotide prevents zonulin-driven tight-junction disassembly, maintaining the integrity of the epithelial barrier. The downstream consequence is reduced paracellular passage of gliadin peptides (and potentially other luminal antigens) into the lamina propria, attenuating the inappropriate adaptive immune response that drives coeliac disease pathology. Critically, larazotide is designed to act at the luminal surface of the intestinal epithelium. It is not substantially absorbed into the systemic circulation at therapeutic doses, which confers the practical safety advantage of limiting systemic drug exposure and off-target effects. This luminal site of action distinguishes larazotide mechanistically from systemically acting immunosuppressants used in refractory coeliac disease. In addition to the zonulin-antagonism model, some in-vitro data suggest that larazotide can directly stabilise the tight-junction protein complex by interacting with ZO-1 scaffolding, though the relative contribution of this receptor-independent effect versus zonulin-receptor blockade remains incompletely resolved.

The Phase IIb trial (Leffler D.A. et al., Gastroenterology, 2015) demonstrated that oral larazotide 0.5 mg TID for 12 weeks produced a statistically significant reduction in gastrointestinal symptom scores in coeliac patients with persistent symptoms on a gluten-free diet — representing the largest clinical dataset for a tight-junction-modulating peptide and proof that pharmacological zonulin antagonism can translate to symptom benefit in humans.

— Notable finding

Research history

Larazotide's development is closely linked to the work of Alessio Fasano, then at the University of Maryland School of Medicine, whose research group characterised the zonulin pathway as a physiological regulator of intestinal permeability and identified elevated zonulin as a feature of coeliac disease, type-1 diabetes, and other autoimmune conditions. The discovery that Vibrio cholerae Zot opened intestinal tight junctions through a receptor-mediated mechanism led to the hypothesis that an antagonist of that receptor could close the paracellular pathway and reduce antigen entry. AT-1001 — the development name for what became larazotide acetate — was derived from a synthetic fragment of the Zot protein sequence engineered to retain receptor-binding affinity while lacking the pore-forming activity of the full toxin. Fasano's group published early characterisation of its tight-junction-modulating properties and demonstrated activity in gliadin-challenge models. The first Phase I and early Phase II data in coeliac patients were published in the mid-2000s. Paterson and colleagues (Aliment Pharmacol Ther, 2007) reported that oral larazotide reduced gluten-induced increases in intestinal permeability (measured by the lactulose/mannitol urinary ratio) in subjects with coeliac disease challenged with gluten-containing meals. This established proof-of-mechanism in human subjects. The landmark Phase IIb trial by Leffler and colleagues (Gastroenterology, 2015) enrolled 342 adult coeliac patients with persistent symptoms despite adherence to a gluten-free diet — a clinically significant unmet need affecting an estimated 20–30% of coeliac patients. The trial tested three oral doses (0.5 mg, 1 mg, and 4 mg three times daily) versus placebo. The 0.5 mg three-times-daily arm produced a statistically significant reduction in the Coeliac Disease Gastrointestinal Symptom Rating Scale (CeD-GSRS) total score at 12 weeks, along with reductions in anti-gluten antibody titres, while the higher doses did not outperform placebo — a phenomenon the authors attributed to possible U-shaped dose–response or receptor kinetics at higher concentrations. Subsequent development has been conducted under the INN-202 designation by 9 Meters Biopharma and its predecessor organisations. A Phase III programme was initiated but the regulatory and commercial trajectory has been subject to change; this reference site does not have access to current unpublished clinical data. Larazotide has also attracted research interest as a conceptual scaffold for the 'leaky gut' field more broadly, including in non-coeliac gluten sensitivity, irritable bowel syndrome, and type-1 diabetes prevention, though evidence in these areas is earlier-stage.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Larazotide acetate has demonstrated a consistently favourable tolerability profile across its clinical-trial programme, which represents the most extensive human safety dataset available for any research peptide targeting the intestinal barrier. In the Phase IIb trial (Leffler et al., Gastroenterology, 2015), the most common adverse events were mild-to-moderate gastrointestinal symptoms, including headache, nausea, flatulence, and abdominal pain. The rate of serious adverse events did not significantly differ between active treatment arms and placebo. No clinically significant changes in laboratory parameters (haematology, biochemistry, urinalysis) were observed. The overall adverse-event profile was comparable between larazotide and placebo, which reflects the fact that the patient population (coeliac disease) has a background of gastrointestinal symptoms that confounds attribution. The principal pharmacological feature underpinning the safety profile is minimal systemic absorption. Because larazotide acts at the luminal surface and does not appreciably enter the systemic circulation, there is no significant exposure of non-gastrointestinal tissues to the drug. This is a fundamental difference from systemically absorbed peptide drugs, which must be considered in the context of distribution, metabolism, and potential off-target effects in every organ. There are no established serious adverse effects attributable to larazotide in the published clinical record. As a foreign octapeptide, immunogenicity is theoretically possible with repeated dosing, but was not a clinical issue in the trials conducted. Long-term safety data beyond 12-week treatment periods are limited in the published record.

UK regulatory status

Larazotide acetate (AT-1001 / INN-202) is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction as of the current date. It is not a controlled substance under the Misuse of Drugs Act 1971. Larazotide is not listed on the World Anti-Doping Agency (WADA) Prohibited List, nor would its pharmacological mechanism (tight-junction modulation, no systemic anabolic or ergogenic effect) obviously fall within any current WADA category. Athletes can obtain clarity from their sport's anti-doping body, but larazotide does not appear to represent a doping concern. No UK MHRA enforcement actions against larazotide supply are known to this publication. Research-grade larazotide acetate for in-vitro and ex-vivo laboratory use is available from research-chemical suppliers; possession for laboratory research is unrestricted. Supply for human administration outside an authorised clinical-trial framework would engage the Human Medicines Regulations 2012. UK patients with coeliac disease and persistent symptoms should discuss management with their gastroenterologist; larazotide is not available as a prescription medicine in the UK.

Frequently asked questions